Lumee™ Oxygen Platform is CE Marked for use in the European Union and all countries that accept the CE Mark. Caution: Investigational Device Limited by Federal (or the United States) Law to Investigational Use.
Profusas first clinical offering, the Lumee™ Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. Potential applications include monitoring of compromised tissue, such as peripheral artery disease.
In the European Union, the Lumee™ Oxygen Platform may help salvage limbs by providing the medical practitioner with a new way to continuously measure tissue oxygen levels in the ischemic limb before, during, and after treatment, enabling appropriate therapy to be administered in a timely fashion before advanced symptoms appear.